{"id":"insulin-secretagogue","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Insulin secretagogues work by binding to and activating the ATP-sensitive potassium channels in the pancreatic beta cells, leading to an increase in intracellular calcium and subsequent insulin release.","oneSentence":"Stimulates the release of insulin from the pancreas.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:37.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT07167693","phase":"PHASE1, PHASE2","title":"Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes","status":"RECRUITING","sponsor":"David K Carroll","startDate":"2025-12-19","conditions":"Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes","enrollment":60},{"nctId":"NCT06606327","phase":"PHASE1","title":"Diazoxide Suppression Test P&F Study","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-10-23","conditions":"Insulin Resistance, Hyperinsulinemia, Obesity","enrollment":10},{"nctId":"NCT07057271","phase":"PHASE3","title":"A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues","status":"COMPLETED","sponsor":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","startDate":"2021-05-27","conditions":"Type 2 Diabetes Mellitus - Poor Control","enrollment":464},{"nctId":"NCT00846872","phase":"PHASE1, PHASE2","title":"Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance","status":"WITHDRAWN","sponsor":"Tulane University Health Sciences Center","startDate":"2008-07","conditions":"Insulin Resistance, Endothelial Dysfunction","enrollment":""},{"nctId":"NCT04279444","phase":"NA","title":"Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"BioKier Inc.","startDate":"2020-06-16","conditions":"Type 2 Diabetes","enrollment":14},{"nctId":"NCT02221284","phase":"","title":"Alogliptin Tablets Specified Drug-use Survey \"Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06-30","conditions":"Type 2 Diabetes Mellitus","enrollment":964},{"nctId":"NCT03421119","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2019-06-20","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT01925248","phase":"NA","title":"Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus, Hyperglycemia","enrollment":32},{"nctId":"NCT01537120","phase":"PHASE1","title":"Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT01077323","phase":"","title":"A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)","enrollment":363766},{"nctId":"NCT01454700","phase":"PHASE4","title":"Effect of CSII and CGM on Progression of Late Diabetic Complications","status":"COMPLETED","sponsor":"Steen Andersen","startDate":"2011-12","conditions":"Type 1 Diabetes Mellitus","enrollment":60},{"nctId":"NCT00332488","phase":"PHASE3","title":"Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2004-12","conditions":"Diabetes Mellitus, Type 2","enrollment":547},{"nctId":"NCT01456130","phase":"PHASE3","title":"Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11","conditions":"Diabetes Mellitus","enrollment":67},{"nctId":"NCT00850096","phase":"PHASE2","title":"Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"CPEX Pharmaceuticals Inc.","startDate":"2009-01","conditions":"Type 2 Diabetes","enrollment":94},{"nctId":"NCT01517321","phase":"PHASE3","title":"MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT00519142","phase":"PHASE3","title":"Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Elixir Pharmaceuticals","startDate":"2007-08","conditions":"Diabetes Mellitus, Type 2","enrollment":367},{"nctId":"NCT00174642","phase":"PHASE3","title":"Opposing Step-by-step Insulin Reinforcement to Intensified Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-12","conditions":"Diabetes Mellitus, Type 2","enrollment":811},{"nctId":"NCT00369148","phase":"PHASE4","title":"Combination of Glinides With Premixed Insulin","status":"COMPLETED","sponsor":"Keio University","startDate":"2004-07","conditions":"Type 2 Diabets Mellitus","enrollment":60},{"nctId":"NCT00461617","phase":"PHASE3","title":"Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2006-08","conditions":"Diabetes","enrollment":291},{"nctId":"NCT00732524","phase":"PHASE4","title":"Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2004-09","conditions":"Type 2 Diabetes","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":550,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"insulin secretagogue","genericName":"insulin secretagogue","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin secretagogues are a class of oral hypoglycemic agents that stimulate the insulin receptor, classified as an agonist. They are used to treat conditions such as type 2 diabetes, insulin resistance, and hyperinsulinemia, and are typically administered orally.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}